breast cancer wearable tech
I am a big fan of this company
Chris Bailey - Director & Co-Founder, Cyrcadia Asia (USA)
Chris is an expert in technology strategy and commercialization who has worked in China and other countries in Asia for over 22 years. As well as being a co-founder and Director of Cyrcadia Asia, he is a partner in Rouse, an intellectual property consulting firm, where he has advised technology companies on their market entry strategies in China in the fields of consumer goods, consumer electronics, cleantech, industrial equipment, automotive and healthcare. He is also an Advisor to Southern Capital Partners, a boutique investment firm based in Shanghai, and several of its portfolio companies. Chris has an MA in Chinese from Oxford University, an LLM in Intellectual Property from the University of Edinburgh and an MBA from the Kellogg / HKUST joint program.
Chris joined CEO Rob Royea in launching Cyrcadia Asia in Hong Kong. Cyrcadia's award-winning technology is a wearable device which uses body sensors and AI to detect breast cancer. The device consists of patches which are worn under a bra for two hours a month. Sensors on the device send data via the users' smartphone app to our cloud-based predictive AI system to detect metabolic change consistent with tumor formation, with a proven accuracy in trials of 83%, as verified against pathology. A report is sent back to the user after two hours, with an alert to her physician if scan is positive. The technology represents a radical improvement against traditional screening methods such as mammography and will be a game-changer in early detection and saving lives, particularly in Asia where screening rates are low and mortality is high. Cyrcadia's technology has already gained a US FDA Class 2 clearance and the final commercial product will be launching in Hong Kong and other ASEAN markets in Q2 2018 on closing its Series A raise.